Article Text

Download PDFPDF
Tissue plasminogen activator therapy for renal venous thrombosis
  1. K Y Wang,
  2. L W Tsai,
  3. C M Chen
  1. Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan
  1. Dr C M Chen, Department of Pediatrics, Taipei Medical University Hospital, 252, Wu-Hsing Street, Taipei 110, Taiwan; cmchen{at}tmu.edu.tw

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Renal venous thrombosis (RVT) is a well-recognised and potentially fatal entity in children, and approximately 80% of RVTs present in the first month of life.1 Management of RVT remains controversial. Anticoagulation or thrombolytic therapy is recommended for bilateral RVT, unilateral RVT with extension of the clot into the inferior vena cava, or impending renal failure.2 We report a case of bilateral RVT in a premature infant who was treated with recombinant tissue plasminogen activator (r-TPA) and had a good outcome with eventual complete recovery.

Case report

A …

View Full Text

Footnotes

  • Competing interests: None.

  • Patient consent: Parental/guardian consent obtained.